Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Ventyx Biosciences (NASDAQ: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. Company executives will engage in a fireside chat on Thursday, June 5, 2025, from 12:50-1:20 PM ET in New York. The presentation will be accessible via webcast on the company's website at www.ventyxbio.com, with a replay available for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, VTYX gained 0.57%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference.
- Event: Jefferies Global Healthcare Conference, New York
Fireside Chat
Date: Thursday, June 5, 2025
Time: 12:50-1:20 PM ET
A webcast of the event will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for ninety days.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.
Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor.
For more information on Ventyx, please visit our website at https://ventyxbio.com.
Investor Relations Contact:
Joyce Allaire
Managing Director
LifeSci Advisors
IR@ventyxbio.com
FAQ
When is Ventyx Biosciences (VTYX) presenting at the Jefferies Healthcare Conference 2025?
Where can I watch Ventyx Biosciences (VTYX) Jefferies conference presentation?
What type of diseases does Ventyx Biosciences (VTYX) focus on?
What is the format of Ventyx Biosciences' (VTYX) presentation at the Jefferies conference?
